CSL in Waltham, Massachusetts, has joined Massachusetts Biotechnology Council (MassBio), a nonprofit organization that advances the state’s leadership in the life sciences.
Massachusetts, especially the Boston corridor, has a vibrant ecosystem of companies, industry thought leaders, universities and hospitals. CSL Waltham’s membership in MassBio provides access to the scientific community, MassBio conferences, networking events, and professional development forums.
In March, CSL’s R&D team opened a 140,000-square-foot facility in Waltham, where researchers will focus on next-generation vaccine technology to protect public health in the decades ahead. Last month, MassBio hosted a lunch-and-learn event onsite for CSL Waltham employees. The MassBio team explained how employees can get involved in local activities and access membership benefits.
“Joining MassBio provides us with another opportunity to raise our profile in the Boston area,” said Ethan Settembre, Vice President of Research for CSL’s Vaccines Innovation Unit. “It will also give us access to the broader life sciences community, enabling potential partnerships and talent recruitment."
With 2,000 employees, CSL's global R&D organization has a presence in King of Prussia, Pennsylvania; Pasadena, California; Melbourne, Australia; Bern, Switzerland; Amsterdam, Netherlands; and Marburg, Germany.
CSL includes business units CSL Behring, which makes medicines for people who have rare and serious diseases; CSL Seqirus, which develops and manufactures vaccines; and CSL Vifor, a leader in iron deficiency and nephrology (kidney care). CSL also operates CSL Plasma, one of the largest collectors of donated human plasma used to make medicines for diseases such as hemophilia and primary immune deficiency.
